Literature DB >> 34422131

Mismatched Imaging Findings of Prostate Cancer Diagnosis: 68 Ga-PSMA PET/CT vs mpMRI.

Egesta Lopci1, Piergiuseppe Colombo2, Massimo Lazzeri3.   

Abstract

Multiparametric magnetic resonance imaging (mpMRI) is the modality of choice for initial diagnosis of prostate cancer (PCa), including biopsy-naïve patients. Nevertheless, clinicians must be aware of the possibility that up to one-fourth of clinically significant cancers might be missed by the modality. Acknowledgment of this occurrence and the increased availability of 68 Ga-PSMA PET/CT in clinical routine, open the door to new, fascinating, indications for this functional modality in the context of PCa detection. With the case herein illustrated, we report a paradigmatic example of mismatch findings between PET/CT and mpMRI better elucidating the potential indication. © Korean Society of Nuclear Medicine 2021.

Entities:  

Keywords:  68 Ga-PSMA PET/CT; Fusion biopsy; MpMRI; Primary diagnosis; Prostate cancer

Year:  2021        PMID: 34422131      PMCID: PMC8322193          DOI: 10.1007/s13139-021-00701-x

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  5 in total

1.  68Ga-PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study.

Authors:  Egesta Lopci; Alberto Saita; Massimo Lazzeri; Giovanni Lughezzani; Piergiuseppe Colombo; Nicolò Maria Buffi; Rodolfo Hurle; Katia Marzo; Roberto Peschechera; Alessio Benetti; Silvia Zandegiacomo; Luisa Pasini; Giuliana Lista; Pasquale Cardone; Angelo Castello; Davide Maffei; Luca Balzarini; Arturo Chiti; Giorgio Guazzoni; Paolo Casale
Journal:  J Urol       Date:  2018-02-01       Impact factor: 7.450

2.  Reply to Michael Froehner, Rainer Koch, and Markus Graefen's Letter to the Editor re: Nicolas Mottet, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2021;79:243-62. Comorbidity Measurement in Patients with Prostate Cancer.

Authors:  Roderick C N van den Bergh; Shane O'Hanlon; Philip Cornford; Nicolas Mottet
Journal:  Eur Urol       Date:  2021-02-16       Impact factor: 20.096

3.  PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancer.

Authors:  E Lopci; G Lughezzani; A Castello; P Colombo; P Casale; A Saita; N M Buffi; G Guazzoni; A Chiti; M Lazzeri
Journal:  Clin Transl Oncol       Date:  2020-05-23       Impact factor: 3.405

4.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.

Authors:  Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Maria De Santis; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Vsevolod B Matveev; Paul C Moldovan; Roderick C N van den Bergh; Thomas Van den Broeck; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Ivo G Schoots; Thomas Wiegel; Philip Cornford
Journal:  Eur Urol       Date:  2016-08-25       Impact factor: 20.096

5.  Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis.

Authors:  Egesta Lopci; Giovanni Lughezzani; Angelo Castello; Alberto Saita; Piergiuseppe Colombo; Rodolfo Hurle; Roberto Peschechera; Alessio Benetti; Silvia Zandegiacomo; Luisa Pasini; Paolo Casale; Diana Pietro; Giulio Bevilacqua; Luca Balzarini; Nicolò Maria Buffi; Giorgio Guazzoni; Massimo Lazzeri
Journal:  Eur Urol Focus       Date:  2020-04-17
  5 in total
  1 in total

1.  Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study.

Authors:  Dong-Xu Qiu; Jian Li; Jin-Wei Zhang; Min-Feng Chen; Xiao-Mei Gao; Yong-Xiang Tang; Ye Zhang; Xiao-Ping Yi; Hong-Ling Yin; Yu Gan; Gui-Lin Wang; Xiong-Bing Zu; Shuo Hu; Yi Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12-03       Impact factor: 10.057

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.